H.C. Wainwright Downgrades Shattuck Labs (STTK) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
Go back to H.C. Wainwright Downgrades Shattuck Labs (STTK) to Neutral
October 1, 2024 9:28 AM EDT
TD Cowen analyst Marc Frahm reiterated a Buy on Shattuck Labs (NASDAQ: STTK).
The analyst commented, "STTK has discontinued the SL-172154 program in HR-MDS/AML based on uncompelling OS separation vs. historical controls. The company is pivoting to a series of anti-DR3... More
October 1, 2024 6:32 AM EDT
Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with cancer and chronic immune-related diseases, today announced a strategic pipeline prioritization to include the discontinuation of its clinical program, SL-172154. The Company will turn its focus to SL-325, its DR3 antagonist antibody, and plans initial clinical development in patients with IBD, where TL1A/DR3 blocking antibodies have demonstrated compelling monotherapy efficacy.
We are disappointed that the promising complete remission rates we... More
